Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 871 Shares

Key Points

• Mark Schoenberg, an insider at Urogen Pharma, sold 871 shares on September 8th at an average price of $19.11, decreasing his position by 0.58% and leaving him with 149,025 shares valued at approximately $2.85 million.
• Urogen Pharma reported a quarterly EPS loss of ($1.05), missing analyst estimates; however, it achieved revenues of $24.22 million, slightly above expectations.
• Institutional ownership of Urogen Pharma stands at 91.29%, with several investors recently increasing their stakes, including Osaic Holdings and Squarepoint Ops, which boosted their holdings significantly in the second quarter.

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 871 shares of Urogen Pharma stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $19.11, for a total value of $16,644.81. Following the transaction, the insider owned 149,025 shares in the company, valued at $2,847,867.75. This trade represents a 0.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Mark Schoenberg also recently made the following trade(s):

• On Monday, August 11th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00.
• On Monday, July 28th, Mark Schoenberg sold 5,149 shares of Urogen Pharma stock. The stock was sold at an average price of $19.14, for a total transaction of $98,551.86.

Urogen Pharma Price Performance

URGN stock traded down $0.73 during trading hours on Tuesday, reaching $20.69. 1,406,924 shares of the stock were exchanged, compared to its average volume of 1,045,916. The firm's 50-day moving average is $17.85 and its 200-day moving average is $12.68. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $21.71. The company has a market cap of $957.12 million, a price-to-earnings ratio of -6.23 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The firm had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. As a group, equities research analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

Institutional Trading of Urogen Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. lifted its position in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company's stock valued at $50,000 after buying an additional 3,070 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Urogen Pharma by 9.4% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company's stock valued at $127,000 after acquiring an additional 797 shares during the period. Squarepoint Ops LLC lifted its holdings in Urogen Pharma by 187.8% during the 2nd quarter. Squarepoint Ops LLC now owns 94,309 shares of the company's stock valued at $1,292,000 after purchasing an additional 61,545 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company's stock valued at $94,000 after purchasing an additional 5,571 shares during the last quarter. Finally, Soleus Capital Management L.P. bought a new position in Urogen Pharma during the second quarter worth $29,934,000. Institutional investors own 91.29% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on URGN shares. Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the stock a "buy" rating in a research report on Friday, June 13th. HC Wainwright reduced their price objective on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating for the company in a research note on Monday, August 11th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Urogen Pharma in a research report on Tuesday, August 5th. Finally, Piper Sandler began coverage on Urogen Pharma in a report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $32.00.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.